Less than one in 10 people eligible to benefit from weight-loss injections such as Wegovy are able to get them, warns the World Health Organization as it issues its inaugural advice on the drugs.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is calling for increased and just availability to this class of drugs.
According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.
"The latest guidelines affirms that obesity is a chronic disease that can be treated with comprehensive and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are key barriers to broad access to the treatments that can aid individuals in losing significant body mass, explains the organization.
Skinny Jab Shortage
Even under the current best projected outlook, the production of such drugs could only cover about 100 million people – fewer than 10% of the global need, as stated by the WHO.
The advice encourages nations and manufacturers to widen availability, via approaches like licensing agreements.
Exclusive production rights on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs mimick a biological compound to delay gastric emptying, curb appetite and enhance satiety so people reduce food intake.
Individuals commonly see weight reduction after several weeks of starting on the weekly injections.
Research indicates people may put most of the weight back on a year later of halting the medication, when their usual food cravings come back.
Being overweight or obese elevates your risk for developing medical conditions, such as diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity concerns people in every country and was associated with millions of deaths worldwide in 2024, as per the health agency.
